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ABSTRACT 
Bisphosphonates (BPs) are prescribed to treat a wide range of skeletal disorders, including 
osteoporosis, Paget disease, osteogenesis imperfecta and primary or secondary bone cancer. 
Their pharmacological action is exerted through the accumulation in areas of active bone 
turnover and the direct inhibition of osteoclast-mediated bone resorption. Indeed, BPs induce 
osteoclast apoptosis by affecting essential pathways of cell metabolism: either forming non-
functional ATP analogues (non-N-containing bisphosphonates) or interfering with mevalonate 
pathway (N-containing bisphosphonates). However, their role in bone formation and a possible 
direct effect on osteoblasts (OBs) is controversial and the determination of BP concentrations 
at different skeletal districts is still an open issue. A serious side effect of the treatment with 
BPs is the osteonecrosis of jaws (BRONJ), a necrotizing and progressive lesion affecting the 
mandibular and/or maxillary bone. This drug-related osteonecrosis, whose etiology is not 
completely unravelled yet, constitutes a severe odontostomatological problem that should not 
be underestimated. 
Here, I present the direct effects of two nitrogen containing bisphosphonates, Alendronate (AL) 
and Zoledronate (ZL), on primary human osteoblast viability, expression and secretion of ECM 
proteins, functional mediators and bone biomarkers. 
Osteoblasts, isolated from patients who underwent total hip replacement surgery at IRCCS 
Galeazzi Orthopaedic Institute, were incubated with several concentrations of AL and ZL (range 
from 10-15 to 10-5M). We never observed any peculiar effect on osteoblast vitality and 
proliferation, except a significant inhibition induced by both drugs at 10-5M, indicating an in 
vitro cytotoxicity. ALP activity was minimally enhanced at day 14 by low BP doses, while higher 
concentrations slightly inhibited it. 
We then investigated the modulation of ECM protein expression after exposure to low, 
intermediate and high BP concentrations (10-13, 10-10 and 10-7M): SPARC was increased at day 7 
by both compounds, while type I Collagen and OPN were clearly down-modulated only by AL. 
The secretion of bone biomarkers and cytokines was also analysed in supernatants of cultured 
osteoblasts at day 3. No overall effect was observed on OPG, DKK1 and IL-6. The levels of 
released TNFα, SOST and IL-1β, all inhibitors of osteoblast differentiation, were slightly 
enhanced by both drugs, independently on their concentrations, while OPN was mildly reduced 
only by 10-7M BPs. Interestingly, DKK-1, IL-6 and OC secretion was increased in all tested 
7 
 
conditions by cells derived from donors <50 years old, suggesting that this subpopulation might 
respond more rapidly to the treatments. 
In conclusion, my results indicate that AL and ZL in concentrations below µM do not overall 
impair osteoblast viability, nor most of the analysed biomarkers. However, since SPARC 
expression, SOST, TNFα and IL-1β secretion are increased, we believe that accumulated doses 
of these BPs may alter bone turnover either through a direct action on bone-forming cells or by 
influencing the release of mediators involved in cell-cell communication. Despite the 
heterogeneity of our samples, I am confident to suggest that the variable in vitro effect of BPs 
on OBs derived from either young or elderly donors might mediate a different therapeutic 
action or an increased risk of developing collateral effects. 
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INTRODUCTION 
BONE TISSUE 
Bone is a highly dynamic and plastic system able to modulate its structure as a result of both 
physiological and mechanical stimuli. It is a type of specialized connective tissue characterized 
by a mineralized extracellular matrix (ECM) that confers remarkable rigidity and strength but, at 
the same time, some degree of elasticity. It is constituted by an organic and an inorganic 
component. The organic part consists of bone cells (osteoprogenitors, osteoblasts, osteocytes 
and osteoclasts) which provide for growth, production and reabsorption of bone tissue, and 
Collagen fibers included in an amorphous substance of non-collagenous proteins. The fibril 
component is arranged differently depending on the type of bone tissue (lamellar or non-
lamellar) and the composition of the organic matrix is subject to slight variations according to 
age, diet and bone type. In details, the non-collagenous organic component of ECM mainly 
consists of: 
- Osteonectin, a Calcium-binding glycoprotein produced by osteoblasts and fibroblasts, 
also known as secreted protein acidic and rich in cysteine (SPARC). It plays a major role 
in bone formation and mineralization and, with the sole exception of Collagen, is the 
most represented protein in bone tissue  
- Osteocalcin, a protein hormone found in bone and dentin, involved in bone 
mineralization and calcium homeostasis. It is uniquely secreted by osteoblasts and 
exerts a pro-osteoblastic, or bone-building, action. At a systemic level, it acts as a 
hormone by inducing pancreatic beta cells to enhance insulin release and at the same 
time stimulating adiponectin secretion by adipocytes  
- Proteoglycans, characterized by the covalent attachment of long chain polysaccharides 
(glycosaminoglycans, GAGs) to different core proteins. GAGs are composed of repeating 
carbohydrate units differently sulfated such as chondroitin sulfate (CS), dermatan 
sulfate (DS), keratan sulfate (KS) and heparin sulfate (HS). They predominantly reside at 
the mineralization front where they participate to matrix organization  
- Glycoproteins, produced at different stages of osteoblast differentiation and 
maturation. They exert a broad array of functions, spanning from control of cell 
proliferation, cell-matrix crosstalk and matrix deposition. Among them, alkaline 
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phosphatase, RGD-containing proteins (osteoadherin, thrombospondin, fibronectin, 
vitronectin, osteopontin, bone sialoprotein), fibrillin and tetranectin are the most 
represented 
While from a qualitative point of view bone organic part is quite similar to cartilage, the 
concentration of proteoglycans is much lower (<1% compared to 35-40% of cartilage) and 
Collagen, mostly type I, becomes the prevalent constituent.  
The inorganic part of bone tissue consists of different mineral salts such as Calcium phosphate 
(85%), Calcium carbonate (10%), Magnesium carbonate (1.5%), Calcium fluoride (0.3%), 
Calcium chloride (2%), citrates and ions (Sodium, Potassium, Magnesium, Zinc and Copper). 
Calcium phosphate is present for the 65% in a crystalline form, mainly hydroxyapatite, and for 
the remaining 35% in an amorphous structure.  
The organic component of the extracellular matrix represents the 35% of bone dry weight and 
confers elasticity to the structure, while the mineralized part is responsible for bone 
compactness and rigidity. Bone contains 99% of the total amount of Calcium and Phosphorus of 
the organism, thus representing the main reservoir for these ions and playing a key role in the 
conservation of their homeostasis. Bone is subject to numerous structural and functional 
changes due to age, nutrition and general health conditions. 
 
BONE HISTOGENESIS AND CLASSIFICATION 
In vertebrates, the skeletal system is composed of cartilage and bone derived from cells 
belonging to three embryonic lineages. The craniofacial skeleton is formed by neural crest cells, 
the axial skeleton derives from paraxial mesoderm while the limb skeleton from lateral plate 
mesoderm. In general, bone always develops by replacement of a pre-existing connective 
tissue. During foetal development, ossification occurs following two different processes: 
- Intramembranous or direct ossification, in which bone is formed directly from primitive 
connective tissue  
- Endochondral ossification, in which bone formation occurs replacing a cartilage model 
Most of the skull bones (including maxilla and mandible) develop through direct ossification 
from mesenchymal structures, while long bones through endochondral ossification. 
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In both processes, matrix deposition is essentially identical. The main difference is that, in 
endochondral ossification, cartilage mass must be removed before bone tissue deposition 
begins (Figure 1).  
 
Figure 1. Scheme of osteogenesis by endochondral ossification (Junqueira's Basic Histology: Text and Atlas, 12
th 
edition). 
 
Bone is firstly deposited in an immature form characterized by Collagen casual organization and 
named woven bone. This draft is then reshaped to form lamellar bone that constitutes most of 
the mature skeleton. Lamellar bone is composed of successive layers, each presenting a finely 
organized superstructure. It can be organized as a single mass (compact bone) or can form a 
spongy mass (cancellous or trabecular bone). Compact bone is present in the diaphysis of long 
bones (where it delimits the marrow cavity) and on the surface of short and flat bones. 
Macroscopically, it is characterized by a homogeneous appearance in the absence of cavities. 
Cancellous bone is typically found in the epiphysis of long bones, underneath a thin layer of 
compact bone, and presents an irregular network of spaces, known as trabeculae. It is a 
strongly vascularized tissue, characterized by a high surface area to mass ratio which allows 
active metabolic exchanges. The histological features and locations of the major types of bone 
are summarized in Table 1.  
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Table 1. Summary of bone types and their histological organization (Junqueira's Basic Histology: Text and Atlas, 
13
th 
edition). 
 
 
BONE CELLS 
Bone cells are represented by osteoprogenitors, osteoblasts, osteocytes and osteoclasts. 
OSTEOPROGENITORS 
They have a mesenchymal origin and share some stem properties with MSCs (mesenchymal 
stem/stromal cells), such as a high proliferation rate and the differentiative potential to form 
osteoblasts. They are found in periosteum and endosteum and, when re-activated, they 
provide for new bone tissue formation. 
OSTEOBLASTS 
Osteoblasts derive from mesenchymal stem/stromal cells that, under appropriate stimulation, 
engage in a differentiation program leading to the formation of osteoprogenitors first and then 
mature osteoblasts (Figure 2). 
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Figure 2. On the left, main steps of osteoblast differentiation from mesenchymal stem cell to terminally 
differentiated osteocyte. Modified from Caplan et al. 2001. 
 
The process of osteoblastic differentiation involves a wide array of developmental cues, 
including signalling proteins and transcription factors. Functionally mature osteoblasts are 
responsible for bone matrix deposition during both intramembranous and endochondral 
ossification. These cells present the morphological and ultrastructural features typical of cells 
responsible for the synthesis and secretion of connective tissue matrix. Osteoblasts are 
relatively small (20-30µm), ovoid or quadrangular cells, characterized by a large nucleus and an 
intensely basophilic cytoplasm with enlarged Golgi apparatus and extensive endoplasmic 
reticulum. They express elevated levels of alkaline phosphatase and synthesize the organic 
component of bone matrix, called osteoid substance. These cells also play a key role in the 
differentiation of their counterpart in bone turnover, osteoclasts.  
 
OSTEOCYTES 
When osteoblasts have completed bone formation and become trapped in the secreted matrix, 
they become osteocytes. Osteocytes are star-shaped cells presenting long cytoplasmic 
extensions. They are housed in bone pits called lacunae and their processes reside in 
microscopic channels called canaliculi, through which they contact each other and blood 
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vessels allowing cell-cell communication and metabolic exchanges. Although osteocytes have a 
very low synthetic activity, they are actively involved in bone turnover regulation following 
mechanical stimulation. 
 
OSTEOCLASTS 
Osteoclasts, unlike other bone cells, belong to the hematopoietic lineage and derive from the 
melting of several (up to 30) monocytic precursors. They are responsible for bone reabsorption 
and remodelling. They are large (150-200µm), multinucleated cells characterized by a 
cytoplasm rich in vesicles and vacuoles. 
 
 
Figure 3. Schematic representation of osteoclast characteristics (Junqueira's Basic Histology: Text and Atlas, 12
th 
edition). 
 
Osteoclasts are highly polarized cells: at sites of active bone resorption, osteoclasts form a 
specialized structure called "ruffled border", an extensively folded membrane organization that 
facilitates bone removal by dramatically increasing cell-matrix contact (Figure 3). They adhere 
to the bone surface creating a sealed area that is acidified through subsequent activation of 
both lysosomal (proteinase and phosphatase) and non-lysosomal (metalloproteinase) 
components. This process starts the cascade that leads to bone matrix erosion through the 
formation of pits called Howship's lacunae. 
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PHYSIOLOGY OF BONE TURNOVER 
Mature bone is a dynamic system subject to a continuous remodelling process involving 
resorption, performed by osteoclasts, and neo-apposition, exerted by osteoblasts. This finely 
tuned replacement mechanism is called bone turnover. The cycle of bone 
absorption/deposition allows replacing worn skeletal tissue with new, mechanically more 
efficient, one. The cellular units designed for this function are osteoclasts, osteoblasts and 
osteocytes. At a molecular level, several chemical mediators acting in an autocrine, paracrine or 
systemic manner finely regulate the remodelling process. Figure 4 shows a scheme of the two 
major molecular mechanisms involved in the regulation of bone turnover: RANK/RANKL/OPG 
and Wnt/β catenin pathways. The process begins with the differentiation of osteoclast 
precursors from the monocyte/macrophage lineage under the control of the Macrophages 
Colony-Stimulating Factor (M-CSF), a cytokine secreted by osteoblasts. Osteoclastogenesis is 
then completed through the activation of the RANK/RANKL/OPG signalling pathway: RANKL 
(Receptor Activator of Nuclear factor Kappa-B Ligand), secreted by osteoblasts and stromal 
cells, binds to its receptor RANK, expressed on the surface of osteoclast precursors. This 
interaction starts a cascade that stimulates the activation of c-jun N-terminal kinase (JNK) and 
nuclear factor kappa-b (NF-kB) pathways, which trigger osteoclast differentiation and 
activation. Osteoblasts further regulate the process by secreting, beside RANKL, also 
Osteoprotegerin (OPG), its soluble decoy receptor.  
Bone deposition, on the other hand, begins with the invasion in the re-absorption gap by 
osteoblasts, responsible for new matrix secretion. Wnt/β catenin pathway plays a key role in 
osseous metabolism, as it promotes bone formation by concurrently inhibiting 
osteoclastogenesis and stimulating osteoblast differentiation, proliferation and activity. The 
activation of this signal pathway occurs after Wnt proteins bind to the receptor complex 
LRP/FZ, triggering the cytoplasmic accumulation of β catenin. Subsequently, β catenin migrates 
to the nucleus where it modifies gene expression by binding to several transcription factors. 
The pathway is finely tuned at multiple levels and its main soluble inhibitors are Sclerostin 
(SOST) and DKK-1, both produced by osteoblasts at different stages of maturation.  
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Figure 4. Overview of RANK/RANKL/OPG and Wnt/β catenin signalling pathways of bone turnover regulation 
(Baron et al. 2013). 
 
In healthy bone, these cellular functions are perfectly balanced in order to maintain constant 
the total bone mass. 
At systemic level, it is known that estrogen, dietary calcium and vitamin D deficiency, 
hyperparathyroidism and therapy with corticosteroids, immunosuppressants or antiblastic 
agents act by bringing the balance between resorption and neo-apposition towards the first, 
while parathyroid hormone (PTH), growth hormone (GH) and Strontium ranelate favour the 
latter.  
The imbalance towards bone resorption, as in the case of osteoporosis and several 
osteometabolic diseases, may cause a weakening of calcified tissue resulting in the increase of 
fractures, either spontaneous or caused by minimal traumatic stress. 
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BISPHOSPHONATES 
HISTORICAL BACKGROUND 
Bisphosphonates (BPs) were firstly synthesized around 1850 when, thanks to their great affinity 
for cations, they found a wide employ as antiscalants in the chemical industry. Just in the early 
sixties, with the first evidences of their avidity toward hydroxyapatite and their ability to 
suppress bone resorption, these compounds found a clinical application in the cure of bone 
remodelling pathologies. Thanks to their ability to powerfully suppress osteoclast activity, 
bisphosphonates became the elective therapy in the treatment of a variety of diseases affecting 
bone metabolism. 
CHEMISTRY 
From a chemical perspective, bisphosphonates are synthetic analogs of pyrophosphate (PPi), a 
compound present in different biological fluids (e.g. plasma, urine and synovial fluid) and 
responsible for preventing ectopic calcification in vivo (Figure 5). 
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Figure 5. Chemical structure of PPi and BPs. R1 and R2, the substituents on the central carbon atom, are shown in 
blue (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12
th
 Edition) 
 
In BPs, P-O-P bound is replaced by a non-hydrolysable P-C-P bridge. This particular structure, 
characterized by the presence of a central tetravalent C atom, allows the bound of side chains 
(R1 and R2). R1 and R2 are responsible for the avidity towards the mineral component of bone 
and for the pharmacological potency. Physiologically, the affinity between hydroxyapatite and 
pyrophosphate depends on the chelating action exerted by its phosphorus atoms towards Ca++ 
ions. In bisphosphonates, this binding potential is enhanced thanks to the presence of hydroxyl 
or primary amine groups in the side chains (Figure 6). Moreover, the chemical composition of 
R2 affects both the resistance to enzymatic degradation and the antiresorptive potency. 
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Figure 6. Chemical composition of R1 and R2 in different bisphosphonates (www.medscape.com) 
 
Depending on the presence or absence of an amine group (-NH2) in R2, bisphosphonates are 
classified as: 
- non-amino bisphosphonates, characterized by short, minimally modified chain 
molecules (Medronate, Etidronate and Clodronate) or a chlorophenol group 
(Tiludronate). They are also known as first-generation compounds 
- amino bisphosphonates, characterized by the presence of an amine group. They are 
further divided into 
- second generation compounds, where R2 is represented by aminoalkyl groups 
(Ibadronate, Alendronate, Pamidronate and Nerhydrate)  
- third generation compounds, presenting a heterocyclic ring in the side chain that 
enhances the relative potency of 100-10000 times compared to other BPs 
(Risedronate and Zoledronate)  
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PHARMACOKINETICS  
Another way of classifying bisphosphonates is based on the different routes of administration, 
distinguishing among those who are orally employed, like Alendronate, Ibandronate or 
Risedronate, and those who are administered intravenously, such as Pamidronate and 
Zolendronate. This distinction has important implications not only from a therapeutic point of 
view, but also in the light of the risk of developing side effects (e.g. osteonecrosis of the jaw). 
Oral bisphosphonates are mainly used in the prevention and treatment of osteoporosis, while 
intravenous bisphosphonates find their clinical application in the cure of malignant diseases, 
such as multiple myeloma and bone metastases, thanks to the higher plasma concentrations 
they can achieve. Indeed, the bioavailability of oral bisphosphonates is very low, usually among 
1-2%: that depends on the small amount of drug that escapes the first-pass liver metabolism 
(Licata 2005). Indicatively, half of the absorbed dose is excreted unchanged through the 
kidneys. The remainder strongly binds to exposed hydroxyapatite crystals, where it can persist 
over a period of months or years and accumulate. It has been shown that binding potential to 
bone surface is lower for the non-amino bisphosphonates Etidronate, Clodronate and 
Tiludronate, while considerably stronger for the amino containing compounds Risedronate, 
Ibandronate, Pamidronate, Alendronate and Zoledronate (Cremers et al. 2011). Moreover, BP 
skeletal distribution and accumulation is not homogenous throughout different skeletal 
districts. Indeed, it has been demonstrated that the uptake of these drugs is generally higher in 
trabecular rather than cortical bone (Weiss et al. 2008) and that they preferentially accumulate 
in areas characterized by active bone turnover (Bauss et al. 2002, Allen 2008). Therefore, the 
pharmacokinetic profile of these compounds is extremely peculiar and complex, as it depends 
on the interaction of various aspects, including type, dose, route of administration, skeletal site 
and duration of treatment. To our knowledge, ex vivo data regarding the actual bisphosphonate 
concentrations achievable at different skeletal districts in treated patients are still not available.  
 
MECHANISM OF ACTION  
The exact mechanism of action of bisphosphonates has not been fully elucidated yet, although 
from the earliest studies it has been suggested that the main target of these compounds might 
be osteoclasts (Boonekamp et al. 1986). Binding to hydroxyapatite crystals, BPs are internalized 
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by these cells during the physiological reabsorption phase of bone remodelling. The compounds 
induce osteoclast apoptosis through a distinct mechanism depending on their chemical 
features: 
- non-amino bisphosphonates, once internalized into osteoclasts, are metabolized and 
converted into non-hydrolysable analogs of ATP. This process leads firstly to metabolic 
deficit and finally to cell death 
- amino bisphosphonates directly interfere with mevalonate pathway (Figure 7), 
inhibiting the key enzyme farnesil-pyrophosphate synthetase. This selective inhibition 
results in the lack of prenylation of different GTPases involved in the maintenance of the 
cell cycle and, eventually, leads to cellular apoptosis (Rodan et al. 2002) 
 
 
Figure 7. Scheme of mevalonate pathway and the inhibiting action exerted by amino bisphosphonates 
(Kharwadkar et al. 2017) 
Another possible mechanism of action of bisphosphonates involves the inhibition of osteoclast 
recruitment and formation. However, experimental evidences concerning this aspect are still 
controversial. Indeed, as some studies demonstrated that BP treatment stimulates osteoclast 
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recruitment (Marshall et al. 1993), in other experimental models an inhibition of 
osteoclastogenesis has been described (Kimachi et al. 2011).  
Recently, an increasing number of evidences has emerged in favour of the hypothesis 
considering OBs as a key target through which BPs exert their action on bone turnover. Indeed, 
it has been demonstrated that these compounds can directly affect osteoblast metabolism, 
although with discordant outcomes, as published data are often contrasting. Several studies 
describe a BP-induced stimulation of osteoblast differentiation and proliferation, together with 
a diminished secretion of soluble factors promoting osteoclastogenesis and osteoclast activity. 
Nevertheless, this anabolic action on bone is not always confirmed, as some reports show that 
high doses of various BPs inhibit osteoblast proliferation, differentiation and osteogenic 
potential. Such contrasting outcomes may be explained by the chemical-structural differences 
of the used compounds, the different employed concentrations, the duration of the treatments 
and the cell types on which the effects are evaluated. Table 2 summarizes the main published 
data regarding in vitro effects of bisphosphonates on osteoblasts and progenitors. 
Despite this clear in vitro demonstration of the effects BPs exert on OBs, their in vivo relevance 
is still uncertain. Indeed, up to now there is no clear evidence on whether the predominant 
therapeutic mechanism of action of these drugs relies on the direct effect on osteoclasts rather 
than the one on osteoblasts and osteoprogenitors. 
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Literature  Drug [ ] M Treated cells Results and overall BP effect 
García-Moreno et al. 1998 
Bone 
AL 10
-11
 to 10
-1
 Human osteoblasts AL≥10
-4
M has a cytotoxic effect. At lower concentrations, no effect on Ca
++
 deposition with a 
tendency in decreasing Collagen synthesis. 
High concentrations of AL are cytotoxic 
Reinholz et al. 2000 
Cancer Res 
PAM 
ZL 
ETI 
10
-10
 to 10
-2
 Immortalized human fetal 
osteoblasts  
PAM in a dose dependent manner decreases cell proliferation and increases ALP activity and Coll I 
secretion. ZL acts similarly to PAM on cell proliferation and mineralization, while ETI is less potent. 
PAM and ZL enhance bone differentiation potential of osteoblasts 
Im et al. 2004 
Biomaterials 
AL 
RIS 
10
-12
 to 10
-4
 Human trabecular bone 
cells and osteoblast-like 
cell line MG-63 
Both BPs enhance cell proliferation and ALP activity. 
10
-8
M concentration increases gene expression of BMP-2, Coll I and OC. 
BPs promote osteoblast proliferation and maturation 
Von Knoch et al. 2005 
Biomaterials 
AL 
RIS 
ZL 
10
-8
 Human bone marrow stem 
cells  
BPs stimulate BMSC proliferation and osteoblast specific gene expression (BMP-2, BSP, RUNX2 and 
Coll I) in a time dependent manner. 
BPs enhance proliferation of progenitors and initiate osteoblastic differentiation 
Naidu et al. 2008 
Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 
AL 
ZL 
10
-6
 to 10
-3
 
10
-6
 to 10
-4
 
Rat osteoblasts Both BPs significantly decrease cell viability in a dose dependent manner.  
TGF-β1 expression was also increased by both treatments.  
BPs increase TGF-β1 secretion and high BP concentrations are cytotoxic 
Idris et al. 2008 
Calcif Tissue Int 
AL 
PAM 
CLO 
ETI 
10
-7
 to 10
-4
 Mouse calvarial 
osteoblasts 
10
-5
M AL and PAM inhibit osteoblast growth, induce apoptosis and inhibit protein prenylation.  
10
-7
M AL and PAM inhibit nodule formation. 
AL and PAM cause osteoblast apoptosis and inhibit differentiation 
Wang et al. 2010 
Biomaterials 
AL 10
-6
 to 10
-5
 Human adipose-derived 
stem cells  
AL increases mineralization, ALP activity and expression of BMP-2. 
AL enhances ADSC osteogenic potential 
Ohe et al. 2012 
Clin Oral Invest 
AL 
PAM 
10
-8
 Human bone marrow stem 
cells  
Both BPs suppress M-CSF (PAM>AL) and upregulate OPG (AL>PAM) gene and protein expression. 
BPs inhibit osteoclastogenesis by acting on osteoclast-osteoblast crosstalk 
Patntirapong et al. 2012 
J Oral Pathol Med 
ZL 10
-8 
to 10
-4
 Murine pre-osteoblastic 
cell line MC3T3-E1 and 
mesenchymal stem cells  
10
-6
M ZL suppresses mineralization of both MC3T3-E1 and MSCs and decreases proliferation. High 
doses inhibit ALP activity and downregulate Coll I, BSP and RUNX2 gene expression. 
ZL inhibits osteoblast proliferation, differentiation and function 
Kaiser et al. 2013 
Breast Cancer Res Treat 
ZL 
IBA 
PAM 
10
-6
 to 10
-4
 Human osteoblasts BPs inhibit osteoblast viability. ZL and PAM induce caspase-dependent apoptosis and decrease Coll I 
and ALP expression while increase OC and BSP. Both BPs strongly reduce CCL2 secretion. 
BPs negatively affect osteoblast viability, proliferation and expression of osteogenic markers 
Casado-Díaz et al. 2013 
Arch Med Res 
RIS 10
-9 
and 10
-8
 Human bone marrow stem 
cells  
RIS enhances BMSC gene expression of RUNX2, ALP, Coll I and OC, ALP activity and matrix 
mineralization. 
RIS positively affects osteogenic differentiation potential 
(continues on next page) 
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Literature  Drug [ ] M Treated cells Results and overall BP effect 
Gronowicz et al. 2014 
Otolaryngol Head Neck 
Surg 
AL 10
-10
 to 10
-8
 Human osteoblasts 
isolated from long bones 
and from stapes of 
patients with otosclerosis 
(OSO) 
No major effect of AL on OBs from long bones. 
In OSO, adhesion, mineralization and RANKL gene expression are decreased in a dose dependent 
manner, while proliferation and OPN gene expression are upregulated. 
AL normalizes the impaired osteoblast properties 
Imai et al. 2015 
Int J Oral Maxillofac Surg 
AL 
RIS 
10
-8
 to 10
-7
 Human mandibular 
fracture haematoma-
derived progenitor cells  
Both BPs significantly decrease proliferation and increase ALP activity. 
BPs increase osteogenic differentiation potential 
Ishtiaq et al. 2015 
Cytokine 
AL 
ZL 
10
-12
 to 10
-6
 Human osteoblastic cell 
lines (MG-63 and HCC1) 
and murine osteocytic cell 
line (MLO-Y4) 
No effect on MLO-Y4.  
Treatment with ZL≥10
-9
M and AL≥10
-7
M significantly decrease VEGF and ANG-1 expression in MG-63 
and HCC1. 
BPs suppress osteoblastic production of angiogenic factors 
Walter et al. 2015 
Biomed Rep 
CLO 
IBA 
PAM 
ZL 
10
-5
 Human umbilical cord vein 
endothelial cells, gingival 
fibroblasts, osteogenic 
cells and oral 
keratinocytes 
BP treatment decreases cell viability. 
Major effects of PAM and ZL are observed in human osteogenic cells. 
Negative effect of BPs on cell viability 
Manzano-Moreno et al. 
2015 
Clin Oral Investig 
PA 
AL 
IBA 
10
-9
 to 10
-5
 Human osteoblast-like cell 
line MG-63 
N-BPs decrease ALP activity, Ca
++
 deposition and expression of co-stimulatory molecules with 
immunologic function (CD54, CD80, CD86 and HLA-DR) while enhance proliferation. 
N-BPs promote osteoblast proliferation and decrease differentiative potential 
Huang et al. 2015 
BMC Musculoskelet Disord 
ZL 10
-6
 and 10
-5
 Human osteoblast-like cell 
lines MG-63 and G-292 
ZL inhibits proliferation, migration and mineralization, while Coll I and OC secretion, ALP activity and 
osteogenic gene expression are not affected. 
ZL affects osteoblast survival and migration but not differentiation 
Huang et al. 2016 
Mol Med Rep 
ZL 10
-8 
to 10
-4
 Murine pre-osteoblastic 
cell line MC3T3-E1 
ZL≥10
-5
M inhibits cell viability and induces apoptosis. 
ZL≤10
-6
M inhibits bone nodule formation, ALP activity, gene and protein expression of Coll I, ALP, OC, 
RUNX2 and BMP-2. 
ZL exerts a dose-dependent inhibitory effect on osteoblast viability and function 
Manzano-Moreno et 
al.2016 
J Oral Maxillofac Surg 
CLO 10
-9
 to 10
-5
 Human osteoblast-like cell 
line MG-63 
CLO stimulates proliferation while decreases ALP activity, Ca
++
 deposition and the expression of 
antigens involved in osteoblast immunologic function (CD54, CD80, CD86 and HLA-DR). 
CLO alters osteoblast physiology and impairs their differentiative potential 
 
Table 2. Overview of the main published data regarding the effects of BP treatment on cells belonging to the osteoblastic lineage (see list of abbreviations). 
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THERAPEUTIC APPLICATIONS 
Bisphosphonates are used in the treatment of many diseases affecting the skeletal system as 
Paget's disease, osteogenesis imperfecta, fibrous dysplasia, osteoporosis, malignant 
hypercalcemia and bone metastases, where they slow down bone resorption. Recently, new 
generation molecules, such as Zoledronate, have been shown to directly inhibit proliferation, 
adhesion and invasiveness of neoplastic cells and modulate neo-angiogenesis, both in vitro and 
in vivo (Zwolak et al. 2013, Clézardin 2013). Table 3 provides a brief overview of the 
bisphosphonates currently approved by FDA together with their clinical indications and 
dosages. 
 
 
Table 3. Main FDA-approved BPs with primary clinical employ, divided according to the administration route 
(www.pharmacytimes.org/landing/283). 
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BISPHOSPHONATES IN NON-ONCOLOGICAL  DISEASES  
The first clinical use of bisphosphonates was in the care of Paget's disease. To date, the 
indications for their employ enlarged to several other benign pathologies affecting bone 
metabolism, including osteogenesis imperfecta, osteoporosis and fibrous dysplasia. 
Since Paget's disease is characterized by a strong increase in bone turnover, bisphosphonates 
represent optimal candidates for its treatment. The primary therapeutic goals are pain relieve 
in the short period and preservation of healthy bone tissue prior the progression of the disease. 
The stage of the pathology, evaluated through the analysis of biological markers, the extent of 
affected bone segments and the manifestation of algic symptoms, is a key factor in choosing 
the type of therapy. Patients showing asymptomatic pagetic lesions or suffering from bone pain 
can be treated per os with Alendronate and Risedronate or intravenously with Pamidronate 
and Zoledronate (Colina et al. 2008).  
Osteogenesis imperfecta is an inherited, autosomal dominant genetic disorder due to 
mutations in COL1A1 or COL1A2 genes. The underlying mechanism is a defective production of 
type I Collagen and symptoms include bone fragility, often leading to multiple fractures, 
disorders of growth and, in the most severe cases, spinal deformities. Prior to the introduction 
of bisphosphonates, the therapeutic options to treat osteogenesis imperfecta were very 
limited. In 1998, the effectiveness of intravenous Pamidronate in increasing bone mineral 
density and reducing fractures was firstly demonstrated (Glorieux et al. 1998) and, from then, 
other bisphosphonates, either orally or intravenously administered, were employed (Dwan et 
al. 2016). 
Osteoporosis is a systemic skeletal disorder characterized by bone mass reduction and 
alteration of bone tissue microarchitecture, resulting in increased bone fragility and ultimately 
in higher fracture risk. The definition itself emphasizes the dual nature of this pathology, 
affecting bone structure both quantitatively (bone mass reduction) and qualitatively (alteration 
of microarchitecture). The main clinical manifestation of osteoporosis is represented by 
fractures. From the age of 50, the risk of osteoporotic fractures is three times greater for 
women, mainly due to physiologically lower bone mass, menopause-induced bone resorption 
and greater incidence of falls. To achieve the goal of fracture prevention, it is therefore 
necessary to act on two fronts: preserve bone mass and reduce, whenever possible, 
concomitant risks. Currently, the pharmacological treatment of osteoporosis relies on inhibitors 
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of bone resorption and in particular on bisphosphonates. The main therapeutic choices 
currently available for the treatment of osteoporosis are reassumed in Table 4. Alendronate is 
approved for the treatment of osteoporosis in men, postmenopausal women and patients with 
glucocorticoid-induced osteoporosis. It has been shown to increase bone mineral density levels 
in postmenopausal women (Bone et al. 2004). Other oral bisphosphonates include Risedronate 
and Ibandronate. In 2012, a randomized trial in men with osteoporosis revealed that 
Zoledronate infusions once a year significantly decreased the risk of developing vertebral 
fractures (Boonen et al. 2012).  
 
 
Table 4. Approved medication for osteoporosis treatment (www.uspharmacist.com) 
 
Fibrous dysplasia is an extremely rare disease characterized by the replacement of bone and 
marrow with fibrous tissue, resulting in the formation of a weak, defective bone. Clinically, it 
manifests itself with pain, bone fractures, skeletal deformities and nervous compression. The 
treatment is mainly palliative but there are some evidences that intravenous bisphosphonates 
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such as Pamidronate or Zoledronate can increase bone density at dysplastic lesions and 
counteract pain (Florez et al. 2016). 
BISPHOSPHONATES IN ONCOLOGY 
At an advanced stage, many malignant neoplasms, among which breast and prostate cancer, 
are characterized by the onset of skeletal metastases and hypercalcemia. Bone metastases 
strongly affect the quality of life of patients, enhancing the risk of developing secondary 
osteoporosis, pathological fractures or vertebral collapse and causing severe pain. Moreover, 
the presence of skeletal metastases significantly reduces the average survival rate of patients 
suffering from solid tumours. The mechanism underlying tumour-derived osteolysis is an 
excessive bone resorption and that constitutes the rationale for bisphosphonate use. Over the 
last 15 years it has been widely demonstrated that BPs can modify the clinical outcome of bone 
metastases reducing by 30-40% the risk of complications (von Moos et al. 2017, Macedo et al. 
2017). The American Society of Clinical Oncology recommends the intravenous administration 
of amino-bisphosphonates in multiple myeloma, prostate and mammary cancer at the first 
evidence of skeletal involvement (Kyle et al. 2007, Dhesy-Thind et al. 2017).  
 
SIDE EFFECTS 
Frequently, the adverse effects linked to bisphosphonate use are described based on their 
route of administration. However, these drugs, both orally or intravenously administered, are 
incorporated into bone mineral matrix and their release requires the activation of bone 
resorption, whose reduction is their primary mode of action. Therefore, bisphosphonates have 
a prolonged residence time and are subject to accumulation in different skeletal districts. This 
potentially unique aspect of bisphosphonate pharmacokinetics must be taken into account 
when considering their long-term safety and side effects. For orally administered 
bisphosphonates, the main side effects are nausea, abdominal pain, esophagitis that can lead 
to ulcerations, flatulence and dyspepsia. Anyway, if BP intake occurs with water at empty 
stomach, these drugs are mostly well tolerated. For intravenous BPs, after the first 
administration the onset of an influenza-like syndrome has been described, whose signs and 
symptoms include fever, leukocytosis, asthenia, muscular and bone pain. However, the 
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symptomatology resolves spontaneously in about 48-96 hours and respond well to the 
administration of NSAIDs (non-steroidal anti-inflammatory drugs).  
In the last decades, the treatment with both oral and intravenous BPs has been associated with 
the onset of a severe odontostomatological condition, the osteonecrosis of the jaw.  
BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW 
Osteonecrosis of the jaw is a disabling and progressive side effect historically associated to 
radio- or chemotherapy and more recently to the use of bisphosphonates. It is defined as 
mandibular or maxillary bone exposure that lasts at least 8 weeks, appearing spontaneously or 
more often as result of odontoiatric procedures such as dental extractions. Since the first 
publication in 2003 by Marx describing the onset of avascular osteonecrosis affecting the 
mandible in patients in treatment with Pamidronate and Zoledronate, the number of case 
reports and studies focused on this pathology has increased dramatically. The incidence of 
BRONJ (Bisphosphonate-Related Osteonerosis of the Jaw) in patients taking oral 
bisphosphonates for osteoporosis is lower than 0.001% against a frequency that can reach up 
to 8-12% in oncologic patients treated intravenously (Lam et al. 2007, Reid et al. 2009). This 
difference depends mainly on two aspects: the peculiar pharmacological potency of the various 
bisphosphonates and the doses and routes of administration. Often, the precipitating event in 
the onset of this complication is a dental extraction, but also other invasive interventions (such 
as periodontal surgery, implantology and apicectomy) can be considered as triggering factors. It 
has been calculated that the risk of avascular osteonecrosis of the jaw in patients taking 
bisphosphonates subject to oral surgery is 4.2 times higher than that of patient following the 
same therapy who don’t undergo dental procedures (Khosla et al. 2007). Anyway, in 25% of 
BRONJ cases no oral intervention occurred: these cases are therefore defined in literature as 
"spontaneous", since the pathology onset is most probably linked to the lack of physiological 
healing following micro traumas. Indeed, the oral cavity is often subject to mechanical stress 
that in normal conditions would cause no damage but in predisposed patients can be the 
triggering factor for BRONJ development.  
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PATHOGENESIS 
The exact mechanisms underlying the development of avascular osteonecrosis of the jaw 
following the use of bisphosphonates are still unknown. However, in the last decade different 
theories have been proposed to explain its onset and several risk factors associated to this 
complication have been determined. One of the main theories considers the drug induced 
impairment of bone turnover as a key etiological factor. Bisphosphonates, as mentioned above, 
directly inhibit osteoclast activity: as consequence, a strong down modulation of osseous 
turnover takes place and bone becomes less resistant to the various stress of daily activity. 
Considering that jaw bones are constantly subject to mechanical forces (e.g. during chewing 
and speaking), it has been hypothesized that, in patients under bisphosphonate medication, 
physiological micro traumas cannot be successfully repaired, due to a diminished remodelling 
ability. Unsolved damages thus become the substrate for osteonecrosis onset. Moreover, after 
dental extraction, the need for repair is even increased.  
Another theory considers soft tissue toxicity as an important mediator of BRONJ development. 
It has been demonstrated that high concentrations of bisphosphonates can exert a cytotoxic 
action on keratinocytes and mucosal cells (Landesberg et al. 2008, Scheper et al. 2010), causing 
an impaired healing process. According to Reid et al., the local release of bisphosphonates may 
depend on the mechanical action exerted by oral surgery. Indeed, he estimates that, after the 
extraction of a dental element, BP concentrations at the alveolar bone can reach levels 100 
times higher respect to the surrounding tissues, thus determining the toxic effects on overlying 
keratinocytes (Reid et al. 2007). Another perspective, based on the mechanism firstly described 
by Sato et al., identifies in acidosis the triggering factor for BP local accumulation (Sato et al. 
1991, Otto et al. 2010). According to the authors, following surgery some bacteria commonly 
found in the oral cavity (e.g. A. israeli, E. coli and B melaninogenicus) determine a pH reduction 
in the wound microenvironment that cause a massive release of bisphosphonates from bone 
matrix. Both alternatives provide also an explanation for the fact that avascular osteonecrosis 
mainly occurs in the maxillo-facial region rather than in other bone districts.  
Finally, also drug-induced hypovascularization has been proposed as a key player in BRONJ 
development. It has been hypothesized that the antiangiogenic effects of bisphosphonates, 
although representing an additional rationale for their employ in oncology, may cause an 
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ischemia-related impairment of tissue homeostasis, local immunity and regenerative potential 
that can trigger the onset of this side effect (Petcu et al. 2012, Sharma et al. 2013). 
As previously mentioned, patients taking intravenous bisphosphonates are more susceptible to 
osteonecrosis onset than the ones under oral therapy, but additional factors play a role in 
determining BRONJ. The associated systemic risks include general health status, genetic 
predisposition and presence of concomitant pathologies (e.g. diabetes, cancer and systemic 
inflammatory disorders). Among the local predisposing factors, a lacking oral hygiene, 
periodontal disease, local injuries and pre-existing oral infections are clearly involved. Other 
known risk factors are alcohol, smoking and advanced age, which itself determines a lower 
resistance to physiological stress of the oral mucosa.  
 
CLINICAL MANAGEMENT OF BRONJ 
In 2007, a task force created by the American Society for Bone and Mineral Research claimed 
that, due to the limited scientific knowledge about BRONJ, no evidence-based guidelines for its 
clinical management were definable (Khosla et al. 2007). From then, different steps forward 
have been performed to unravel some of the aspects of BRONJ etiopathogenesis and now 
common principles for its treatment can be traced. Above all, oral cavity health in patients 
taking BPs is unanimously recommended. The last update of the American Association of Oral 
and Maxillofacial Surgeons draws a clear picture of the current knowledge and the research 
status in this field, providing new guidelines to address multiple clinical scenarios (Ruggiero et 
al. 2014). In BRONJ prevention and treatment, we can either face:  
1. Patients waiting to undergo BP therapy 
2. Patients in treatment with BPs without evidences of BRONJ onset 
3. Patients with established BRONJ 
In the first case, it is mandatory the recognition of any potential infectious process affecting 
dental or periodontal tissues through a full oral examination, comprehensive of radiographic 
analysis, in order to diagnose and cure any septic process. In the presence of potential 
infectious foci, their eradication is necessary. Bacterial decontamination therapies, such as 
endodontic and periodontal therapies and dental extractions, should be carried out in the time 
span between the first visit and the onset of BP therapy. In delineating the treatment plan, the 
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risk of leaving infectious diseases should not be underestimated in these patients, therefore it 
is recommended to follow strict diagnostic criteria. In particular, dental elements with 
uncertain prognosis should be extracted without attempting conservative approaches. 
Odontostomatological interventions can be multiple and often require time to ensure their 
effectiveness. One of the key issues in managing these patients is indeed the limited 
procrastinability of BP therapies, given the severe pathological pictures in which these drugs 
are often prescribed. Therefore, a close cooperation between oncologist, odontostomatologist 
and patient is absolutely desirable. 
The purpose of the clinical management of patients already under BP therapy is to avoid any 
invasive intervention that may cause the stimulation of bone remodeling. These patients can 
indeed undergo all odontostomatological therapies just avoiding those procedures that can 
trigger bone healing processes. Unlike the previous scenario, dental extractions should be as far 
as possible avoided and, in case of dental or periodontal injuries, conservative approaches 
should be considered the first therapeutic choice. It has been demonstrated that, in these 
patients, the risk of developing osteonecrotic lesions can increase after invasive oral 
procedures (Abu-Id et al. 2008, Utreja et al. 2013), even though it has been recently proposed 
that topical infectious conditions, rather than extraction itself, may be the crucial player in 
BRONJ onset (Otto et al. 2015). 
The main objectives in the care of patients with full-blown BRONJ are pain elimination, control 
of the infection affecting soft and hard tissues and arrest of pathology progression. Currently, 
different alternatives are indicated in the treatments of osteonecrosis (Fliefel et al. 2015, 
Bermúdez-Bejaranon et al. 2017). Depending on stage, symptomatology and absence or 
presence of necrotic bone exposure, the therapeutic options involve:  
- conservative treatment, with analgesics, antibiotics, antiseptics and antifungals 
- surgical treatment, both minimally invasive (e.g. debridement of the exposed area and 
sequestrectomy) or invasive (marginal or segmental resection with reconstruction of 
defective bone and soft tissues) 
- adjuvant therapies (platelet rich plasma, low level laser irradiation, bone morphogenic 
protein, teriparatide, ozone, hyperbaric oxygen and photodynamic therapy)  
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AIM 
Bisphosphonates are widely employed in the clinical practice but their exact mechanism of 
action has not been fully elucidated yet. Beside the catabolic action on osteoclasts, a role in 
bone formation through a direct effect on osteoblasts has been hypothesized. Prolonged 
treatments are associated with the occurrence of an odontostomatological complication, the 
osteonecrosis of the jaw, whose etiopathogenesis is still unclear. Studies in vitro regarding the 
effect of these compounds on cells belonging to the osteogenic lineage are often controversial. 
Moreover, most published results rely on the use of immortalized cell lines, frequently of 
murine origin.  
The aim of this study was to evaluate Alendronate and Zoledronate action on primary human 
osteoblasts harvested from a wide patient cohort, in the attempt to find a mechanism that may 
shed light on the onset and evolution of bisphosphonate-related osteonecrosis of the jaw. In 
details, we investigated metabolic and functional characteristics of osteoblasts after acute or 
chronic exposure to a wide concentration range of both drugs. Particular attention was paid to 
the influence of bisphosphonate treatment on mediators involved in the crosstalk among bone 
cells.  
Furthermore, given the lack of ex vivo data regarding the accumulation of bisphosphonates, an 
additional aim of our work was the establishment of a collection of bone specimens with the 
perspective of evaluating bisphosphonate concentrations in long bones. 
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MATERIALS AND METHODS 
If not otherwise stated, reagents were provided by Sigma-Aldrich. 
ESTABILISHMENT OF PRIMARY CULTURES 
SAMPLE COLLECTION 
Bone specimens were obtained from the femoral head of patients undergoing total hip 
replacement at IRCCS Galeazzi Orthopaedic Institute. Samples were collected as waste 
materials to be used for research purposes, following procedure PQ 7.5.125, version 4, dated 
22.01.2015, approved by the Institute. Personal data of each patient, including age, gender, 
medical anamnesis and potential history of bisphosphonate therapy, were gathered and 
considered for the group assignment. A summary of the collected samples is reported in Table 
5. 
ISOLATION AND EXPANSION OF PRIMARY HUMAN OSTEOBLASTS 
Harvested femoral heads were positioned into saline filled containers and transferred from the 
surgery room to the lab, where samples were manipulated under sterile conditions (Figure 8), 
following Taylor et al. with some modifications. Briefly, trabecular bone was excised with a 
scalpel, minced into fragments and washed several times with PBS (Phosphate Buffered Saline, 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4 x 7H2O, 1.4mM KH2PO4 at pH 7.4) in order to 
remove residual adipose and hematopoietic tissue. Between the several washes, samples were 
vortexed to further favour the removal of contaminants and debris. Bone chips were then 
placed in 60mm tissue culture dishes in cDMEM, Dulbecco's Modified Eagle's Medium 
supplemented with 10% FBS (Hyclone EuroClone), 2mM L-glutamine, 50U/ml penicillin and 
50μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2. Portions of bone 
material were also stored at -80°C for further analyses (e.g. HPLC-MS). Culture media were 
changed twice a week. Osteoblasts (OBs) outgrowing from the explants reached confluence in 
about 2-3 weeks, then cells were detached with 0.5% trypsin/0.2% EDTA and sub-cultured 
every 2 weeks.  
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Table 5. Collected samples and donor characteristics. For all samples, a portion of bone material was stored at -
80°C. NT: not treated with bisphosphonates. AL: in treatment with Alendronate. 
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Figure 8. Manipulation of femoral head for osteoblast isolation. (A) Saline filled container from the surgical room. 
(B) Femoral head. (C) Extraction of fragments from trabecular bone. (D) Removal of debries and contaminant 
tissues by vortexing. (E) Excised bone chips placed in tissue culture dish with appropriate medium.  
 
PRIMARY HUMAN OSTEOBLAST CHARACTERIZATION 
To confirm the osteoblast phenotype, populations were characterized for morphology, growth 
rate, collagen production and the expression of typical osteoblast markers. 
Morphology was evaluated after DiffQuik staining (Medion Diagnostics), following the kit 
protocol, and images were taken through Olympus BX51 microscope. 
Population doubling time (DT) was assessed during subsequent culture passages as follows:  
DT=∆t x ln(2)/ln(N/N0) 
where N and N0 represent the number of collected and plated cells respectively, and ∆t the 
time span between passages. 
To quantify collagen production, 8x103 cells/cm2 were cultured in 24-well plates. After 14 days, 
cells were fixed in Bouin’s solution and then incubated 60 min with 0.1% Sirius Red F3BA in 
saturated picric acid. After washing with 10mM HCl, staining was extracted with 1M NaOH and 
absorbance read at 550nm with Wallac Victor II plate reader (Perkin Elmer). Obtained values 
were interpolated in a standard curve of calf Collagen (range 5-80µg) to quantify matrix 
deposition. Osteocalcin and Osteopontin expression was confirmed performing 
immunofluorescence (IF) experiments. Briefly, cells were seeded on round coverslips and 
cultured for about a week. Samples were then rinsed twice with PBS, fixed with 4% 
paraformaldehyde for 20 min and permeabilized with 0.1% Triton X-100 for 2 min. Primary 
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antibodies were incubated overnight at 4°C. After two washes with PBS+1% BSA (Bovine Serum 
Albumin), specific binding was revealed by incubating fixed OBs with secondary antibodies at 
room temperature for 45 min. Probed antibodies are listed in Table 6. After two washes in 
PBS+1% BSA, cover slips were mounted using ProLong® Diamond Antifade Mountant with DAPI 
(Thermo Fisher Scientific) and analysed by wide field fluorescence microscopy (Olympus BX51). 
 
 
Table 6. List of primary (A) and secondary (B) antibodies used in IF experiments. 
 
For Western Blot (WB) analysis, OBs were lysed in 65mM Tris-HCl at pH 6.8 and 2% SDS 
(Sodium Dodecyl Sulfate) supplemented with protease inhibitor cocktail (104mM AEBSF, 
1.4mM E-64, 4mM bestadin, 2mM leupeptin, 80μM aprotinin and 1.5mM pepstatin A) and 
1mM PMSF (Phenyl Methane Sulfonyl Fluoride). Samples were centrifuged at 14000 g for 10 
min at 4°C to remove cell membranes and protein content was determined using BCA™ Protein 
Assay (Pierce Biotechnology). Briefly, 2 and 4μl of each lysate were dosed in 96-well plates 
adding 200μl of CuSO4 and bicinchoninic acid solution, following the manufacturing instruction. 
The plate was incubated at 37°C for 30 min and then read at 550nm using with Wallac Victor II 
plate reader. Protein concentration was inferred by interpolating the absorbance on a standard 
curve of BSA (concentration range 0.125-2mg/ml). 20µg of cell extracts were resolved in SDS-
PAGE and transferred to a nitrocellulose membrane (GE Healthcare). To both check transfer 
37 
 
efficiency and assess sample homogeneity, Ponceau S reversible stain was performed. 
Membranes were then probed over night with primary antibodies directed against different 
bone markers. Proteins of interest were detected after 45 min incubation with HRP-conjugated 
secondary antibodies using Westar Supernova chemiluminescent substrate (Cyanagen). The list 
of employed antibodies is reported in Table 7. Images were acquired through ChemiDoc 
Imaging System™ and analysed through Image Lab™ software (Bio-Rad). 
 
 
Table 7. Primary (A) and secondary (B) antibodies used in WB experiments. HRP: horseradish peroxidase. 
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TREATMENTS WITH BISPHOSPHONATES 
EXPOSURE TO BISPHOSPHONATES 
The nitrogen containing bisphosphonates Alendronate (AL, Y0001727 Sigma-Aldrich) and 
Zoledronate (ZL, SML0223 Sigma-Aldrich) were dissolved in sterile double distilled water 
(ddH2O) at the final concentration of 6.9mM, then aliquoted and kept at -20°C until their 
further use. 24 hours after seeding, osteoblasts were exposed to several concentrations of both 
drugs. For all the experiments, untreated cells were cultured in parallel. The wide BP 
concentration range used for the treatments, spanning from 10-15M to 10-5M, was based on in 
vitro literature (Table 2) and derived on the lack of ex vivo data on BP accumulation at different 
skeletal districts. 
ALAMARBLUE® VIABILITY ASSAY 
To test cell viability, 3x103 cells/cm2 in triplicate were seeded in 96-well plates. 24 hours later, 
cells were treated with selected concentrations of Alendronate and Zoledronate following the 
experimental set up shown in Figure 9.  
 
 
Figure 9. Treatments with Alendronate and Zoledronate. Arrows indicate drug administration, (A) and (B) 
represent the single and repeated treatment set up respectively. 
 
At each time point (day 2, 5, 9 and 12), culture media were replaced with 200μl of cDMEM 
+10% AlamarBlue® (Thermo Fisher Scientific) and OBs were incubated for 3 hours and 30 min at 
37°C in the dark. 100µl of supernatants were then transferred to black bottom 96-well plates 
and fluorescence (540nm excitation λ, 600nm emission λ) was read with Wallac Victor II plate 
reader. 
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ALP ACTIVITY ASSESSMENT 
5x103 OBs/cm2 were maintained in culture on 24-wells plates in the presence or absence of 
selected concentrations of AL and ZL spanning from 10-13 to 10-6M. After either 7 or 14 days, 
cells were washed in PBS, lysed in 50µl of 0.1% Triton X-100 and quantified through BCA™ 
Protein Assay. Alkaline phosphatase (ALP) enzymatic activity was assessed through a 
colorimetric assay based on the conversion of p-nitrophenyl phosphate (pNPP), a colourless 
substrate, into p-nitrophenol (pNP), a yellow product. Briefly, 5-10µg of cell lysates were 
incubated in 96-well plates at 37°C with 100µl of substrate solution (10mM p-
nitrophenylphosphate dissolved in 100mM diethanolamine and 0.5mM MgCl2 at pH 10.5). 
When the colorimetric reaction occurred, samples were read at 405nm through Wallac Victor II 
plate reader. Absorbance values were interpolated with a standard curve of pNP (range 12.5-
400μM) and ezymatic activity (U) was calculated considering the amount of produced pNP and 
the reaction time as follows: 
U=μM pNP/min 
ALP activity was then normalized to each sample protein content and expressed as U/µg. 
ANALYSIS OF BONE BIOMARKERS PRODUCED BY POOLED PRIMARY OSTEOBLASTS 
To both minimize donor-related variability and optimize our experimental set up, we decided to 
perform the further experiments on pooled osteoblast populations, an approach described as 
particularly convenient when investigating primary human cells (Ketterl et al. 2015, Nieto-
Nicolau et al. 2016). While this strategy allows to reduce variability both within and between 
experiments, its major disadvantage is represented by the loss of statistical power. To 
overcome this issue, we performed multiple experiments using various donor pools. Every pool 
consisted of cells deriving from three patients and was created by mixing an identical number 
of cells for each population at the same culture passage. The description of pool characteristics 
is shown in Table 8.  
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Table 8. Pool description according to donor characteristics. 
 
Pooled OBs were seeded at a density of 1.5x104/cm2 and treated with 10-13, 10-10 and 10-7M AL 
or ZL for 7 days. In parallel, control cells were also grown in standard conditions. Conditioned 
media were collected at day 3 after treatment, centrifuged at 2000g for 5 min to remove dead 
cells and debries, then stored at -20°C for further WB or Luminex analyses. Moreover, at day 7 
cell lysates of each group were obtained and quantified by BCA™ Protein Assay. Western Blot 
analysis was performed following the procedure previously described with either 20µg of 
intracellular proteins or 10µl of supernatants for each condition. The probed antibodies are 
listed in Table 7. 
In addition, selected bone biomarkers and cytokines present in conditioned media were also 
quantified by Luminex assay. The MILLIPLEX MAP Human Bone Magnetic Bead Panel-Bone 
Metabolism Multiplex Assay (#HBNMAG-51K Millipore) was customized to contain 9 key 
analytes of osseous intracellular crosstalk: DKK1, IL-6, TNFα, OPG, OC, OPN, SOST, IL-1β and 
FGF23. Duplicates of conditioned media for each condition (25µl/sample) were analysed and 
the assay was performed following standard procedures (Figure 10). Briefly, samples were 
incubated overnight at 4°C with a mix of magnetic beads coated with specific capture 
antibodies. Each antibody-immobilized bead set recognizes and binds a specific analyte in a 
spectrally distinct region, allowing its univocal identification by the instrument. After incubation 
with detection antibodies first and then with Streptavidin-Phycoerythrin conjugate, the plate 
was read through Luminex xMAP® system (Luminex) to simultaneously assess and quantify the 
presence of the different analytes in each sample.  
 
41 
 
 
Figure 10. Luminex assay procedure. (A) Step by step description of the assay. (B) Overview of the Luminex 
detection scheme (www.thermofisher.com). (C) List of the human bone antibody-immobilized magnetic beads. 
 
IL-6 levels were measured in 1:5 diluted samples and, for technical reasons, only 10-10 and 10-
7M BP concentrations were tested. Data analysis was performed with MAGPIX xPONENT 4.2 
software (Luminex). 
STATISTICAL ANALYSIS 
Unless otherwise stated, data are expressed as mean±SEM. Statistical analysis was performed 
by one-way analysis of variance (ANOVA) using GraphPad Prism 5. Differences were considered 
significant at p≤0.05.  
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RESULTS 
ISOLATION, CULTURE AND CHARACTERIZATION OF PRIMARY HUMAN 
OSTEOBLASTS 
In collaboration with the clinicians at the IRCCS Galeazzi Orthopaedic Insitute, we collected 
bone specimens from 46 patients (27 males and 19 females) who underwent total hip 
replacement. We harvested primary cultures from 35 samples, obtained from 22 males and 13 
females, with age spanning between 43 and 78 years. For osteoblast isolation, fragments of 
trabecular bone were placed in tissue culture dishes and cell primary outgrowth from the 
explants occurred spontaneously within a week (Figure 11 A). In 2-3 weeks, cells reached 
confluence, then were detached and analysed to assess osteoblast phenotype.  
Morphological analysis, carried out on both living and stained cells (Figure 11 B and C 
respectively), confirmed the ovoidal/polygonal shape and the dimension range (around 20-
30µm in diameter) typical of osteoblasts. Doubling time was calculated during subsequent 
culture passages and was quite different among populations, with a mean value of 177.8±83.5 
hours (n=13). Despite a short lag phase after thawing, growth rate was not affected by 
cryopreservation (data not shown). ECM secreting ability was confirmed looking at Collagen 
deposition through Sirius Red staining, as shown in Figure 11 D. At day 14, Collagen secretion 
was 6.6±1 µg/104 seeded cells (n=4). Osteoblast lysates were analysed by Western Blot for the 
specific expression of bone ECM components, in particular type I Collagen, Osteopontin and 
Osteonectin, all essential components of osseous organic matrix (Figure 11 E). Furthermore, the 
expression of Osteocalcin, a bone-building protein hormone secreted solely by osteoblasts, and 
Osteopontin was confirmed by immunofluorescence stainings (Figure 11 F and G respectively). 
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Figure 11. Characterization of primary osteoblast cultures. Phase contrast images of (A) cell outgrowth from 
trabecular bone 1 week after withdrawal and (B) osteoblasts cultured for 2 weeks. (C) DiffQuik staining of fixed 
osteoblasts. (D) Sirius Red staining of Collagen produced in 14 days by 4 different osteoblast populations. (E) WB 
analysis on 20µg of OB1 and OB2 lysates for the expression of type I Collagen, Osteopontin, Osteonectin and 
GAPDH. (F) and (G) Immunofluorescence images of Osteocalcin (F) and Osteopontin (G) expression in primary 
osteoblasts. On the left, single fluorescence channels are represented separately (upper panels, red and green 
emission for OC and OPN, respectively; lower panels, nuclei counterstained with DAPI). On the right, merged 
images are shown. Scale bars indicate 100µm. 
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CELL VIABILITY AFTER BP TREATMENT 
Once assessed the phenotype of isolated cells and obtained stable primary osteoblast 
populations, our first aim was to investigate a possible effect of a single BP administration on 
cell vitality and proliferation. 24 hours after seeding, osteoblasts were exposed to AL or ZL at 
concentrations ranging from 10-15 to 10-9M and viability was monitored up to 12 days. At day 2, 
single treatments with BPs≥10-11M mildly inhibited cell viability of about -10% respect to 
control (Figure 12 panel A and B). However, cells treated with ZL rapidly and efficiently 
recovered their growth rate over time, while AL-treated osteoblasts appeared more 
susceptible. Indeed, at day 12 the initial inhibitory effect of ZL treatment completely 
disappeared, whereas 10-11 and 10-9M AL interference seemed maintained, although this 
negative trend was not statistically significant.  
Then, we decided to monitor osteoblast viability after chronically treating cells with BP 
concentrations up to 10-5M. For both drugs, concentrations below µM did not exert any clear 
overall effect on cell viability. Starting from day 5, repeated treatments with 10-5M AL slightly 
decreased cell viability. At day 9, this reduction became statistically significant and, at day 12, it 
reached a decrease of -23.2±8.2% respect to untreated osteoblasts (Figure 12 C). Differently, 
10-5M ZL exerted a pronounced cytotoxic effect on osteoblasts that affected cell morphology 
already at day 2, when cells showed the first signs of metabolic and apoptotic stress as 
acquirement of a rounder shape and increased vacuole secretion (data not shown). At day 5, ZL 
inhibitory action was already higher than the one observed after chronic administration of 10-
5M AL and, at day 12, cell viability reached a decrease of -68.7±18.3% respect to untreated cells 
(Figure 12 D). 
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Figure 12. Influence of BP treatment on osteoblast viability. Single treatment with AL (A) and ZL (B), concentrations 
from 10
-15
 to 10
-9
M. Repeated treatments with AL (C) and ZL (D), concentrations from 10
-15
 to 10
-5
M. Data are 
represented as relative values setting as 100% the viability of untreated osteoblasts at every time point (ctrl, blue 
dashed lines). In the repeated administration set up, red arrows indicate additional pharmacological treatments. 
Data are expressed as mean±SEM of at least 3 independent experiments for each condition. Statistical significance 
versus ctrl is expressed as *p<0.05, **p<0.01 and ***p<0.001.  
 
Overall, a great inter-donor variability was observed in the response of primary osteoblasts to 
the drugs. Interestingly, this variance was not linked to donor characteristics such as gender or 
age, while it seemed to correlate with the growth kinetics of the different primary populations. 
Indeed, as shown in Figure 13, ZL from 10-11 to 10-7M, administered either once (panel A) or 
repeatedly (B), stimulated the viability of a highly proliferating osteoblast population (DT=132 
hours) isolated from a female 47 y/o donor, whereas the same ZL concentrations exerted a 
slightly negative action on cells characterized by a slower metabolism (data not shown). 
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Figure 13. ZL effect on viability of a highly proliferating osteoblast population. Single (A) or repeated (B) ZL 
treatments, concentrations from 10
-13
 to 10
-7
M. In the repeated administration set up, red arrows indicate 
additional pharmacological treatments. Data are expressed as arbitrary fluorescence units (AFU) and represented 
as mean±SD of 3 technical replicates. 
 
BP INFLUENCE ON ALP ACTIVITY 
Based on the limited influence of BP treatments on cell viability, we decided to investigate their 
effect on alkaline phosphatase activity, a well-recognized marker of osteoblast maturation. The 
action of AL and ZL from 10-13 to 10-7M on ALP activity levels was evaluated both at 7 (Figure 14 
A and B) and 14 days (C and D). Overall, at day 7 BPs did not exert any univocal effect and, 
among the different populations, no trend in osteoblast response was definable, considering 
either the type of drug or the applied concentration. 
Interestingly, at day 14, osteoblast response to AL treatment was still extremely variable while, 
for ZL, a dose response trend was discernible. Indeed, low doses of ZL≤10-10M enhanced ALP 
activity of about +25% respect to control, while higher ones (ZL≥10-9M) slightly decreased it (-
12.6% for 10-9M, -11.3% for 10-8M and -21.2% for 10-7M). As expected based on viability results, 
treatments with µM concentrations of both compounds had an inhibitory effect on this 
osteoblast-specific functional parameter (data not shown).  
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Figure 14. Effect of BP administration on osteoblast ALP activity. Concentrations from 10
-13
 to 10
-7
M of AL (A, C) 
and ZL (B, D) at day 7 and 14, respectively. Data are represented as relative values setting as 100% the ALP activity 
of untreated osteoblasts (ctrl, blue dashed lines). Results are expressed as mean±SEM of at least 3 independent 
experiments for each condition.  
 
We still found that BP effect on primary osteoblasts was quite variable and no relationship 
between donor age or gender and OB response was clearly evident. For instance, at day 14, 10-
7M AL mildly inhibited 2 out of the 3 tested primary populations (-18% of basal ALP activity in 
cells deriving from a 56 y/o female donor, -53% in cells from a 59 y/o male patient), while it 
strongly stimulated the third one (+62% in osteoblasts deriving from a 46 y/o woman). In any 
case, the analysis of BP effects on cells derived from patients younger than 50 y/o revealed the 
absence of any age-related trend. Considering that BP action on cell viability seemed to depend 
on the unique metabolic footprint of each cell population rather than on patient characteristics, 
we looked at our data also in this perspective. However, this analysis did not allow unravelling 
any correlation between OB physiological properties and response to the drugs. As a proof of 
concept, Figure 15 shows the inhibitory action of both AL and ZL (panel A and B respectively) at 
concentrations higher than 10-13M, despite the variable ALP activity of each population (0.6 
U/µg for OB6, male 69 y/o donor, and 0.07 U/µg for OB8, male 66 y/o patient). 
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Figure 15. BP effect on ALP activity of metabolically different osteoblasts. AL (A) and ZL (B) from 10
-13
 to 10
-9
M on 
OB6 and OB8 at day 14. Data are expressed as enzymatic units per µg of cell lysate (U/µg) and shown as mean±SD 
of 3 technical replicates. 
 
EXPRESSION AND SECRETION OF BONE BIOMARKERS AND CYTOKINES AFTER BP 
TREATMENT 
To minimize the observed donor-related variability, we decided to follow an approach 
described in several scientific works, that is to perform the experiments on pooled primary 
cells. Therefore, we set up 4 osteoblast pools, including a pool constituted with cells deriving 
solely from donors younger than 50 y/o and one with osteoblasts from elderly patients (>60 
y/o). Then, we treated pooled cells with 3 representative BP concentrations selected out of the 
initial wide range: low (10-13M), intermediate (10-10M) and high (10-7M). At first, we analysed 
the intracellular expression of several osteoblast markers after 7 days of treatments (Figure 16). 
 
 
Figure 16. Representative WB analysis of cell lysates. 20µg of protein lysates derived from osteoblasts grown in 
standard conditions (-) or treated for 7 days with 10
-13
, 10
-10 
or 10
-7
M BPs were analysed. Specific bands 
corresponding to Coll I, OPN, SPARC, β Tubulin and GAPDH expression were revealed at the appropriate molecular 
weights.  
49 
 
AL down modulated Coll I and OPN expression in a dose related manner, while ZL general effect 
on these ECM markers was absent, independently from the applied concentration (Figure 17 
panel A and B, respectively). In detail, 10-7M AL significantly inhibited Coll I expression of -
56.7±5.3% and distinctly downregulated OPN (-19.4±8.8%) respect to untreated cells. In 
contrast, both drugs mildly upregulated intracellular SPARC levels.  
 
 
 
Figure 17. Modulation of Coll I, OPN and SPARC expression by osteoblasts treated for 7 days with 10
-13
, 10
-10
 or 10
-
7
M AL (A) or ZL (B). For each sample, analytes were normalized on housekeeping proteins (either β Tubulin or 
GAPDH). Data are expressed as relative values setting as 100% Coll I, OPN or SPARC expression by untreated 
osteoblasts (ctrl, blue dashed lines). Results are represented as mean±SEM of 4 independent experiments for each 
condition. Statistical significance versus ctrl is expressed as **p<0.01. 
 
Since we wanted to investigate a possible rapid osteoblast response to BP exposure, we then 
analysed the secretion levels of several bone biomarkers and cytokines in the supernatants of 
cultured osteoblasts. In details, we quantified DKK-1, OPG, OPN, OC, SOST, TNFα, IL-1β, IL-6 and 
FGF-23 release in the presence of AL or ZL for 3 days.  
 
 
Table 9. Basal levels of released molecules by 4 osteoblast pools. 1.5x10
4
/cm
2
 cells were maintained for 3 days in 
4ml of cDMEM. Data are expressed as pg/ml and derive from 2 technical replicates for each pool. Undetectable 
levels are indicated as “-“. 
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As reported in Table 9, among the different cell pools the basal secretion levels of most 
proteins by untreated osteoblasts was within the same order of magnitude. The major 
differences were observed in OPN release, that was about 6.5 times higher by pool 1, obtained 
from heterogeneous donors (Table 8). As expected, FGF-23 levels were undetectable, since it is 
mostly secreted by osteocytes.  
 
Figure 18. BP effect on protein secretion. Release by pooled primary human osteoblasts of DKK-1, OPG, OPN, OC, 
SOST, TNFα, IL-1β and IL-6 evaluated at day 3 after treatment with 3 concentrations (10
-13
, 10
-10
 and 10
-7
M) of AL 
(A) and ZL (B). Data are represented as relative values setting as 100% the amount of proteins released by 
untreated osteoblasts (ctrl, blue dashed lines). Results are expressed as mean±SEM of 4 independent experiments.  
 
As shown in Figure 18, the overall secretion of DKK-1, OPG and IL-6 was not affected by the 
administration of AL (panel A) or ZL (B), while OPN levels were slightly down modulated by both 
BPs in a dose dependent manner. Indeed, 10-7M AL or ZL treatment decreased OPN release of -
7.9±2% and -8.9±5% respectively. Interestingly, the inhibited OPN secretion by 10-7M AL 
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corroborates with the reduction of its expression at day 7 shown in Figure 17. SOST, TNFα and 
IL-1β secretion was slightly enhanced by both drugs following a dose related gaussian trend, 
with the only exception of AL effect on IL-1β release. Specifically, 10-10M AL enhanced SOST and 
TNFα release of+12.1±6% and +18.6±7% respectively, while 10-10M ZL stimulated SOST, TNFα 
and IL-1β secretion of about +16%. At last, OC secretion seemed to be overall stimulated by 
BPs, even though the observed high variability has to be mentioned. 
Surprisingly, when we analysed separately each osteoblast pool, we discovered that the 
secretion of 3 analytes displayed an age-related trend.  
 
 
 
Figure 19. Effect of AL (A) and ZL (B) on protein secretion according to donor age. DKK-1, IL-6 and OC release by 
pooled osteoblasts analysed after 3 days of treatment with 10
-13
,10
-10
 or 10
-7
M BPs. Data are shown separately 
according to donor age and expressed as relative values setting as 100% the amount of proteins secreted by 
untreated osteoblasts (ctrl, blue dashed lines). Green and purple frames highlight the different response to BP 
treatment among osteoblasts harvested from donors younger than 50 y/o and older than 60 y/o, respectively. For 
broad age range group (40<x<70 y/o), data derive from mean±SEM of 2 independent experiments. ND: not 
detectable. 
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In particular, both drugs slightly stimulated DKK-1 and IL-6 release in osteoblasts isolated from 
donors younger than 50 y/o, while reduced it in cells harvested from patients older than 60 y/o 
(Figure 19). Furthermore, OC secretion was strongly enhanced by BPs in cells belonging to the 
youngest subset, while either downregulated by AL (panel A) or unaffected by ZL (panel B) in 
osteoblasts derived from elderly donors. A peculiar age-related trend for OPG, OPN, SOST, 
TNFα or IL-1β secretion was never observed. 
Since SPARC expression was upregulated by osteoblasts treated with BPs for 7 days (Figure 17), 
we investigated if also its early secretion was affected (Figure 20). 
 
 
 
Figure 20. Representative WB analysis of culture supernatants. 10µl of culture supernatants from osteoblasts 
grown in standard conditions (-) or treated with 10
-13
, 10
-10 
or 10
-7
M BPs for 3 days were analysed. A) Ponceau S 
stain. B) Specific bands corresponding to SPARC were revealed at the appropriate molecular weight (~43kDa). 
 
Both BP treatments slightly stimulated SPARC release (Figure 21): indeed, low and intermediate 
AL doses similarly increased its secretion more than +50% respect to untreated cells, while ZL 
produced the highest induction when administered at 10-13M dose (+64.6±28.1%). These last 
results on SPARC release confirm what previously observed for its intracellular expression.  
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Figure 21. Modulation of SPARC secretion by osteoblasts treated for 3 days with 10
-13
,10
-10
 or 10
-7
M AL (A) or ZL 
(B). Data are expressed as relative values setting as 100% SPARC release by untreated osteoblasts (ctrl, blue 
dashed lines). Results are represented as mean±SEM of a least 4 independent experiments for each condition. 
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DISCUSSION 
Bisphosphonates represent the elective treatment for several bone diseases associated with 
increased osteoclast activity. Although their primary mechanism of action relies on the 
inhibition of osteoclasts, recent evidences suggest that BPs interfere directly with other 
recipient cells. In particular osteoblasts, the anabolic counterpart of bone turnover, have been 
indicated as important additional targets. Indeed, even though with conflicting results 
depending on the experimental approach, a direct effect of BP treatment on osteoblast 
metabolism has been demonstrated (Table 2). The mechanism by which bisphosphonates are 
internalized by osteoclasts during the resorptive process has been unravelled, whereas little is 
known about their incorporation into other cells. Using fluorescence labelled bisphosphonate 
analogs, it has been demonstrated that osteoclasts internalize the compounds through a 
mechanism of fluid-phase endocytosis (Thompson et al. 2006). On the contrary, the uptake and 
the internalization of these drugs into the cytoplasm of non-resorbing cells has only been 
hypothesized, mainly based on experimental evidences of their effect. Several in vitro studies 
have documented BP inhibitory action on a variety of cell types, including cancer cells (Karlic et 
al. 2017), endothelial progenitors (Sharma et al. 2016) and mature vascular cells (Walter et al. 
2010). In 2008 Coxon et al. firstly described the different responses of resorbing and non-
resorbing cells to both soluble and mineral-bound BPs. The authors demonstrated that 
macrophages and osteoblasts grown in monocultures could internalize only small amounts of 
drugs from the mineralized matrix. On the contrary, when cells were co-cultured with 
osteoclasts the internalization rate was higher, indicating that the release of bisphosphonates 
from calcified matrix mediated by osteoclast action could affect neighbouring targets (Coxon et 
al. 2008). Auspiciously, further studies will eventually shed a light on this aspect of BP 
pharmacodynamics. 
Bisphosphonates present high avidity towards bone, preferentially at sites of increased bone 
remodelling, where they can reside for a prolonged period and accumulate. Due to the unique 
pharmacokinetics of these molecules, the current knowledge on BP distribution in bone tissue 
is still limited and the skeletal concentrations are mostly inferred from serum levels or derive 
from preclinical models. Up to now, ex-vivo measurements of BP concentrations in human bone 
biopsies are not available. According to the literature, representative levels are estimated in the 
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range between 10-12 and 10-9M (Cremers et al. 2011, Ribeiro et al. 2014), but reachable 
concentrations in bones characterized by a high turnover, like maxilla and mandible, are 
probably higher.  
Although widely used in the clinical practice, prolonged treatments with bisphosphonates are 
associated to impairment or suppression of bone formation in vivo (Tobias et al. 1993, Odvina 
et al. 2005) and predispose to the onset of side effects such as osteonecrosis of the jaw. Since 
the exact mechanism underlying the development of this complication is not fully understood 
yet, the need to investigate the effects exerted by BPs on all components of bone milieu 
remains concrete. Recent studies have shown that BRONJ onset is more frequent in patients 
under therapy with amino-bisphosphonates, mostly due to their higher potency and increased 
incorporation rate into mineral tissues (Otto et al. 2012). Therefore, considering also the variety 
of bisphosphonate-treated bone diseases, for our research we selected two drugs: 
Alendronate, orally administered in the prevention and treatment of osteoporosis, and 
Zoledronate, the most potent of nitrogen-containing bisphosphonates, intravenously 
prescribed in cancer patients. 
We started evaluating a wide BP concentration range, based on previous in vitro reports and 
considering the difficulty in selecting levels that can be representative of bone 
microenvironment under therapeutic dosages. 
Our results, even though subject to a substantial inter-donor variability, show that high 
concentrations of both tested BPs reduce osteoblast viability and proliferation. Moreover, also 
alkaline phosphatase activity decreases in relation to the administered drug concentration. 
Even though in the literature most differences in BP action are described among nitrogen and 
non-nitrogen containing compounds (Idris et al. 2008), we found that identical doses of 
molecules belonging to the same class can behave differently. Indeed, in our hands the order of 
potency was ZL over AL. Our finding is in accordance to what described by Ishtiaq et al. looking 
at osteoblast release of angiogenic factors (Ishtiaq et al. 2015) and it fully reflects the 
description of bisphosphonate in vivo pharmacological potency (Rogers et al. 2000). Anyway, 
the molecular mechanisms underlying the maintenance of this hierarchy in vitro still need to be 
understood.  
Taken together, our data partly corroborate with the hypothesis of a dual nature of BP action 
on cells belonging to the osteoblastic lineage depending on dosage, recently resumed by 
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Maruotti et al.: an inhibitory effect at concentrations higher than 10−6 M and a stimulatory one 
at lower doses (see also Table 2). In our experimental model, a positive effect of BP treatment 
at concentrations below µM is not always evident. In the case of viability interference, we 
found a high variability that seems to depend on the metabolic characteristics of each primary 
population. Indeed, highly proliferating osteoblasts were positively affected by the treatments. 
A differential effect of bisphosphonate treatment depending on cell growth rate was recently 
described also by Karlic et al.: the authors gave evidence of a higher sensitivity to drug exposure 
of fast-growing cancer cell lines over slowly proliferating ones. The underlying causes can be 
multiple and still need to be defined, anyway we hypothesize that a differential rate in BP 
uptake among metabolically slow and rapid cells could be a critical factor. 
In previous studies, most experiments are performed on immortalized cell lines, often even of 
murine origins. Therefore, we want to highlight the relevance of the use of primary human 
osteoblasts, being in our opinion more representative, as they more closely mimic the in vivo 
scenario. Moreover, thanks to a close collaboration with the surgeons at IRCCS Galeazzi 
Orthopaedic Institute, we have analysed cells from a heterogeneous patient cohort, enrolling 
donors of both genders (22 males and 13 females) and wide age range (from 43 to 78 years 
old).  
To optimize our experimental approach, we implemented a strategy often followed by groups 
working with primary human populations: the creation of cell pools. As recently discussed by 
Stoddart et al., the main criticality linked to the use of pooled cultures, beside a diminished 
statistical power, is the loss of information regarding each individual population behaviour (e.g. 
leaving unsolved the question “do all donors respond to the treatment at the same extent or is 
there a donor-related variation?”). On the other hand, we want to point out the relevance of 
the results thus obtained, since the outcome per se represents the average of n different 
populations: if a certain effect on a population depends on serendipity, following this approach 
its influence on the cumulative result will be most probably minimized.  
Excluding the µM doses due to their cytotoxicity, we treated the pooled osteoblasts with either 
high (10-7M), intermediate (10-10M) or a low (10-13M) concentrations of AL or ZL.  
We found a different modulation of the intracellular production of several ECM proteins 
depending on BP type. Indeed, while cell response to ZL resulted very variable, AL treatments 
exerted a dose-related inhibition of type I Collagen and Osteopontin expression. In contrast 
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with our results on cell viability and ALP activity, where ZL produced the major effects, this 
higher AL influence on osteoblast expression of structural proteins raises important questions 
regarding the exact mechanism of action of these drugs. This discrepancy can depend on 
several factors and, in this case, beside the hypothesized differential internalization rate in 
osteoblasts, we suggest a possible interference on distinct molecular pathways between the 
two drugs. We strongly believe that this aspect requires further investigations. 
Since we demonstrated that BPs can directly affect the metabolic and functional features of 
bone-forming osteoblasts, we investigated a possible influence on the release of soluble 
mediators involved in cell crosstalk within bone milieu. Indeed, cell-cell interactions, either 
dependent on direct contact or mediated by autocrine and paracrine effectors, play a key role 
in the osseous microenvironment, finely tuning the balance between bone resorption and 
formation. To our knowledge, this kind of broad-spectrum analysis on the influence of 
bisphosphonates on bone crosstalk has never been documented. Moreover, taking advantage 
of the high sensitivity of Luminex technique, we have concurrently detected any minimal 
fluctuation in the secretion levels of several analytes. 
Interestingly, the effect of AL and ZL seemed catabolic on bone formation, since an overall 
increase in the secretion of inhibitors of osteoblast differentiation acting at distinct levels was 
depicted. In details, AL and ZL treatments upregulated the secretion of TNFα and IL-1β, pro-
inflammatory cytokines known to inhibit osteoblast differentiation and stimulate bone 
resorption (Abbas et al. 2003, Kwan Tat et al. 2004). Furthermore, BP administration increased 
the release of SOST, a soluble inhibitor of osteoblastogenesis acting on Wnt/β catenin pathway 
(Baron et al. 2013). In accordance with the evidence of a BP-dependent catabolic effect on 
bone, we also described a diminished secretion of Osteopontin by treated cells. In contrast, 
Osteonectin release was mildly stimulated. Interestingly, osteoblasts harvested from donors 
younger than 50 y/o seemed to respond more rapidly to BP exposure, increasing also the 
secretion levels of DKK-1 and IL-6, both negative mediators in osteoblast differentiation 
(Pinzone et al. 2009, Kaneshiro et al. 2014). 
Based on the overall described effects, we hypothesize that BP catabolic action within bone 
microenvironment may, at least partially, contribute to BRONJ development. In details, we 
suggest that, when osteoblasts are exposed to BPs in pre-pathological conditions, their rapid 
response may determine an unbalance of the remodelling cycle that, in synergy with other 
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predisposing factors (e.g. bone microdamage, inflammation) and drug effects (such as soft 
tissue toxicity, inhibition of angiogenesis), concurs to the pathology onset (Figure 22). 
 
 
Figure 22. Proposed mechanism by which BPs exert a catabolic action on bone formation acting directly on 
osteoblasts. Depending on drug concentration, BPs can either exert a cytotoxic action or impair osteoblastogenesis 
and ECM deposition. This unbalance of bone physiology can work in synergy with other predisposing factors, laying 
the ground to BRONJ development. 
 
 
Our results support previous hypotheses that progressive drug accumulation may impair 
osteogenesis. However, as mentioned before, the cut off level between therapeutic and 
negative action of BPs is conventionally set at the μM level (Maruotti et al. 2012). Here we 
demonstrate that also lower doses may interfere with bone formation acting on the crosstalk 
between bone cells. Nevertheless, it is mandatory to mention that the transposition in vivo of 
the obtained results should be cautious. Indeed, the impact on bone microenvironment of the 
catabolic effect mediated by BPs on OBs we demonstrated in vitro should be confirmed by 
further studies.  
FINAL REMARKS 
The nitrogen-containing bisphosphonates AL and ZL exert direct effects on cell viability and 
several functional properties of human primary osteoblasts, depending on the type of 
compound and the applied concentration. BP-induced alterations on the expression of 
extracellular matrix components and the release of soluble mediators may imply structural 
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changes of bone architecture and affect essential interactions within the osseous milieu. We 
hypothesize that the catabolic effect on bone crosstalk observed after BP exposure may be 
clinically related to the onset and evolution of bisphosphonate-related osteonecrosis of the 
jaw. 
FUTURE PERSPECTIVES 
In the attempt to shed a light on the mechanisms of BRONJ onset, we are currently amplifying 
our investigations on BP effects on bone formation following different strategies: 
- Translating our in vitro results in a preclinical model, in order to better understand their 
implications in an in vivo scenario. We consider employing Danio rerio (zebrafish), since 
it represents a convenient and powerful animal model to investigate bone development 
and remodelling (Pasqualetti et al. 2015)  
- Analysing BP concentrations ex vivo. We are evaluating the medical records of the 
donors enrolled in this study to detect a possible history of BP use. Up to day, out of 28 
screened clinical registers we found 1 positive match for the use of Alendronate (Table 
5). Once gathered an adequate number of positive samples, we are planning to analyse 
BP levels through HPLC/MS techniques in the attempt to reveal a relationship with the 
type of therapy followed by the patient (e.g. compound, route of administration, 
duration, time from suspension) and/or the occurrence of side effects  
- Investigating BP influence on osteoblast precursors. For most of enrolled donors, we 
harvested also mesenchymal stem/stromal cells from bone marrow (n=25). We plan to 
investigate BP direct effects on these progenitors too, following the experimental set up 
employed for osteoblasts. In addition, since we are particularly interested in BP 
influence on cell-cell interactions, we will further study this aspect using different 
approaches, based either on co-cultures (both direct and indirect) or on the 
administration to progenitors of the secretome derived from treated osteoblasts, the 
latter being an innovative strategy of great interest in our lab (Brini et al. 2017, Gualerzi 
et al. 2017)  
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Impact of Dental Implant Surface Modications on  
Adhesion and Proliferation of Primary Human  
Gingival Keratinocytes and Progenitor Cells
The success of dental implants depends mainly on osseointegration and gingival 
sealing. Therefore, early attachment and spreading of epithelial cells might be 
critical for a positive outcome. Research in dental implant materials has primarily 
focused on surface roughness, de!ned by the average roughness (Ra) index, as it 
promotes the process of osseointegration. This study explored its in"uence on soft 
tissue attachment by looking mainly at adhesion, proliferation, and spreading of 
primary human cells belonging to the epithelial lineage. Characterized as human 
gingival keratinocytes, gingival and epithelial progenitor cells were seeded on 
machined (S1; Ra = 0.3 to 0.6 µm), Ti-Unite (S2; Ra = 1.2 µm) and SLA (S3; Ra = 2 µm) 
implants. Cell adhesion and early proliferation and spreading were evaluated by 
combining a biochemical vitality test with imaging analyses. Findings showed that 
adhesion on S1 (36% ± 2%) and S2 (44% ± 7%) was signi!cantly higher than on S3 
(23% ± 6%), while early proliferation was slightly improved on S1. The resulting data, 
obtained through an innovative and easily reproducible in vitro method, suggest 
that implant surface roughness affects epithelial cell adhesion and proliferation. 
Int J Periodontics Restorative Dent 2018;38:XXX–XXX. doi: 10.11607/prd.3304
Since the mid-1960s, dental im-
plants have been successfully used 
to treat edentulous patients, with a 
survival rate higher than 90% after 
15 years.1 In the last decades, sever-
al physical and chemical treatments 
of the titanium surface have im-
proved its biocompatibility in terms 
of biosafety and biofunctionality. 
Good clinical performance of an im-
plant depends on osseointegration 
(ie, the formation of an effective in-
terface between implant and bone) 
and gingival attachment, which oc-
curs via the junctional epithelium 
(JE).2 Several studies have primarily 
focused on bone response, leading 
to the development of surface op-
timization strategies to allow rapid 
osseointegration and to improve the 
strength and stability of bone-im-
plant interaction.3 It is widely accept-
ed that rough surfaces, compared 
with machined ones, favor greater 
osteoblast anchorage, facilitating 
osseointegration.4 However, as peri-
implantitis represents a major cause 
of implant loss, recent research has 
focused on the interface between 
prosthesis and peri-implant soft 
tissues, stressing the importance 
of an adequate biologic seal.5 This 
mucosal attachment consists of con-
nective and epithelial components 
and protects the underlying tissues, 
such as alveolar bone, from bacteria 
and other pathogens. The epithelial 
attachment, being in direct contact 
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Raman spectroscopy uncovers 
biochemical tissue-related features 
of extracellular vesicles from 
mesenchymal stromal cells
Alice Gualerzi  1, Stefania Niada2,3, Chiara Giannasi2,3, Silvia Picciolini1,4, Carlo Morasso  1, 
Renzo Vanna1, Valeria Rossella5, Massimo Masserini4, Marzia Bedoni1, Fabio Ciceri6, Maria 
Ester Bernardo5, Anna Teresa Brini2,3 & Furio Gramatica1
Extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) are emerging as valuable therapeutic 
agents for tissue regeneration and immunomodulation, but their clinical applications have so far been 
limited by the technical restraints of current isolation and characterisation procedures. This study 
shows for the first time the successful application of Raman spectroscopy as label-free, sensitive and 
reproducible means of carrying out the routine bulk characterisation of MSC-derived vesicles before 
their use in vitro or in vivo, thus promoting the translation of EV research to clinical practice. The Raman 
spectra of the EVs of bone marrow and adipose tissue-derived MSCs were compared with human 
dermal fibroblast EVs in order to demonstrate the ability of the method to distinguish the vesicles of 
the three cytotypes automatically with an accuracy of 93.7%. Our data attribute a Raman fingerprint 
to EVs from undifferentiated and differentiated cells of diverse tissue origin, and provide insights into 
the biochemical characteristics of EVs from different sources and into the differential contribution of 
sphingomyelin, gangliosides and phosphatidilcholine to the Raman spectra themselves.
Extracellular vesicles (EVs) are a heterogeneous group of membrane-bound vesicles that are constitutively 
released by cells of different tissue origins. Past controversies concerning nomenclature have now been resolved 
by the scientific community, which defines EVs as the group of particles made up of exosomes, microvesicles and 
apoptotic bodies1. Exosomes (30–100 nm) and microvesicles (up to 1000 nm) differ in size and cellular origin, but 
both mediate intercellular communication within a tissue and among organs thanks to body fluid transportation1.
As is the case for most body cells, part of the secretome of mesenchymal stromal cells (MSCs) includes 
exosomes and microvesicles, which are currently being investigated because of their striking regenerative and 
immunomodulating potential. The bioactive molecules loaded onto/into EVs are involved in the paracrine effects 
of stem cells, and even the membrane constituents of vesicles seem to trigger intracellular protective/regener-
ative pathways in recipient cells2. It has been suggested that MSC-derived EVs may be sometimes even more 
therapeutically valuable than whole cells, because of their remarkable handling advantages, which can accelerate 
their clinical application in the so-called cell therapy without cells3. The possibility of overcoming the cell therapy 
drawbacks of having to administer living, replicating and difficult to control cells is currently one of the main 
challenges facing regenerative medicine, and EVs can be an effective means of stimulating the restoration of 
organ function through tissue regeneration and repair in the context of an integrated strategy of regenerative 
rehabilitation4.
Over the last ten years, many studies have demonstrated the role that MSC-derived EVs can play in tissue 
repair and immunomodulation5, 6 and, in 2014, EVs ability to influence the activity of recipient cells and regulate 
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